Septal Myectomy and Concomitant Coronary Artery Bypass Grafting for Patients With Hypertrophic Cardiomyopathy and Coronary Artery Disease
Related Experiment Video
Updated: Dec 27, 2025

Author Spotlight: Enhancing Coronary Artery Revascularization
Published on: September 15, 2023
Anita Nguyen1, Hartzell V Schaff1, Ahmed F Sedeek1
1Department of Cardiovascular Surgery, Mayo Clinic, Rochester, MN.
Insights
Patients with hypertrophic cardiomyopathy undergoing septal myectomy and coronary artery bypass grafting (CABG) face increased mortality risk. This study highlights CABG as a significant predictor of late death in these complex cases.
Area of Science:
- Cardiology
- Cardiac Surgery
- Clinical Outcomes
Background:
- Severe coronary artery disease (CAD) increases mortality in hypertrophic cardiomyopathy (HCM) patients.
- Limited data exists on the long-term impact of coronary revascularization during septal myectomy.
Purpose of the Study:
- To evaluate the effect of concomitant coronary artery bypass grafting (CABG) on mortality in patients undergoing transaortic septal myectomy for HCM.
- To identify risk factors for mortality in this patient population.
Main Methods:
- Retrospective analysis of 2913 adult patients undergoing septal myectomy between 1961 and 2017.
- Comparison of baseline characteristics and outcomes between patients with and without concomitant CABG.
- Multivariable analysis to identify independent predictors of all-cause mortality.
Main Results:
- Concomitant CABG was performed in 8.4% of patients and was associated with older age and male sex.
- Operative mortality was higher in the CABG group (2.2% vs 0.8%).
- Multivariable analysis identified concomitant CABG (HR 1.89), older age, atrial fibrillation, diabetes, higher BMI, and earlier surgery as mortality risk factors.
Conclusions:
- Obstructive coronary artery disease requiring CABG during septal myectomy is a significant risk factor for late mortality in HCM patients.
- Careful patient selection and risk stratification are crucial for those requiring combined procedures.
Abstract:
Severe coronary artery disease is associated with disproportionately increased risks of death in patients with hypertrophic cardiomyopathy. There is a paucity of data on the long-term effect of coronary revascularization at the time of myectomy. Between January 1, 1961, and October 31, 2017, 2913 adult patients underwent transaortic septal myectomy at Mayo Clinic. Concomitant coronary artery bypass grafting (CABG) was performed in 246 (8.4%). We compared baseline characteristics of patients who underwent septal myectomy with and without CABG and assessed the effect of surgical revascularization on the risk of all-cause mortality. Patients who underwent concomitant CABG were older (median [interquartile range], 66.3 [59.8-72.1] years vs 54.4 [43.5-64.8] years; P<.0001) and more likely to be male (63.0% vs 54.2%; P=.008) than those who did not undergo coronary revascularization at operation. There was no significant difference in preoperative left ventricular outflow tract gradients (55 [25-81] mm Hg vs 58 [25-88] mm Hg; P=.116). Overall operative mortality (≤30 days after surgery) was 1.0% and higher in patients who underwent concomitant CABG (2.2% vs 0.8%; P=.048). In multivariable analysis (n=2641), factors independently associated with mortality included concomitant CABG (hazard ratio [95% CI], 1.89 [1.39-2.58]; P<.0001), older age at operation (per interquartile range increase, 2.79 [1.95-3.98]; P<.0001), atrial fibrillation (1.46 [1.11-1.92]; P=.006), diabetes (1.45 [1.04-2.04]; P=.031), higher body mass index (change from 0.95 to 0.5 quantile, 1.95 [1.46-2.59]; P<.0001), and surgery performed earlier in the study period (2.02 [1.31-3.11]; P=.001). In conclusion, obstructive coronary artery disease severe enough to prompt concomitant CABG at the time of septal myectomy is an important risk factor for late mortality.
More Related Videos
Related Concept Videos
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Cardiomyopathy V: Interprofessional Care
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Mitral Stenosis III: Medical Management

